Ginkgo biloba: Evaluation of CYP2C9 drug interactions in vitro and in vivo

American Journal of Therapeutics

Volumn 13, Issue 1, 2006, Pages 24-31

  Mohutsky, Michael A ^a,b   Anderson, Gail D ^a   Miller, John W ^a   Elmer, Gary W ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

CYP2C9; Diclofenac; Ginkgo biloba; Pharmacokinetics; Tolbutamide

Indexed keywords

CYTOCHROME P450 2C9; DICLOFENAC; GINKGO BILOBA EXTRACT; TOLBUTAMIDE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HYDROLYSIS; DRUG INHIBITION; DRUG METABOLISM; DRUG OXIDATION; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME METABOLISM; MALE; NORMAL HUMAN; PRIORITY JOURNAL; STEADY STATE;

ADULT; ARYL HYDROCARBON HYDROXYLASES; DICLOFENAC; DRUG SYNERGISM; FEMALE; GINKGO BILOBA; HERB-DRUG INTERACTIONS; HUMANS; MALE; MICROSOMES, LIVER; PLANT EXTRACTS; TOLBUTAMIDE;

EID: 31544472883     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000143695.68285.31     Document Type: Article

References (40)

1. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997. JAMA. 1998;280:1569-1575.
2. Hasler A, Gross GA, Meier B, et al. Complex flavonol glycosides from the leaves of Ginkgo biloba. Phytochemistry. 1992;31:1391-1394.
3. Sticher O. Quality of Ginkgo preparations. Planta Med. 1993;59:2-11., 88-90
4. McKenna DJ, Jones K, Hughes K. Efficacy, safety, and use of ginkgo biloba in clinical and preclinical applications. Altern Ther Health Med. 2001;7:70-86.
5. Le Bars PL, Katz MM, Berman N, et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA. 1997;278:1327-1332.
6. Pittler MH, Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. Am J Med. 2000;108:276-281.
7. Mix JA, Crews WD Jr. A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings. Hum Psychopharmacol. 2002;17:267-277.
8. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology. 1996;46:1775-1776.
9. Gilbert GJ. Ginkgo biloba. Neurology. 1997;48:1137.
10. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. N Engl J Med. 1997;336:1108.
11. Benjamin J, Muir T, Briggs K, et al. A case of cerebral haemorrhage - can Ginkgo biloba be implicated? Postgrad Med J. 2001;77:112-113.
12. Matthews MK. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology. 1998;50:1933-1934.
13. Chung KF, Dent G, McCusker M, et al. Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man. Lancet. 1987;1:248-251.
14. Gurley BJ, Gardner SF, Hubbard MA, et al. Cytochrorne P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther. 2002;72:276-287.
15. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variation in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: studies with the microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270:414-423.
16. Rettie AE, Eddy AC, Heimark LD, et al. Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab Dispos. 1989;17:265-270.
17. Rettie AE, Koop DR, Haining RL. CYP2C. In: Levy RH, Thummel KE, Trager WF, et al, eds. Metabolic Drug Interactions. Philadelphia: Lippincott Williams & Wilkins; 2000:75-86.
18. Pharmacopeia US. United States Pharmacopeial Convention Inc. Rockville, MD,2002.
19. Estabrook RW, Rosebrough NJ, Farr AL, et al. The spectrophotometric measurement of cytochromes assessed with drug metabolism. Methods Pharmacol. 1972;2:303-350.
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
21. Lopez-Garcia MP, Dansette PM, Mansuy D. Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. Biochemistry. 1994;33:166-175.
22. Lang D, Böcker R. Highly sensitive and specific high-performance liquid chromatographic analysis of 7-hydroxywarfarin, a marker for human cytochrome P-4502C9 activity. J Chromatogr B Biomed Appl. 1995;672:305-309.
23. Shimamoto J, Ieiri I, Urae A, et al. Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele. Eur J Clin Pharmacol. 2000;56:65-68.
24. Haining RL, Jones JP, Henne KR, et al. Enzymatic determinants of the substrate specificity of CYP2C9: role of B′-C loop residues in providing the pi-stacking anchor site for warfarin binding. Biochemistry. 1999;38:3285-3292.
25. Veronese ME, Miners JO, Randles D, et al. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther. 1990;47:403-411.
26. Hollman PC, van Trijp JM, Buysman MN, et al. Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man. FEBS Lett. 1997;418:152-156.
27. He N, Edeki T. The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am J Ther. 2004;11:206-212.
28. Lemmens HJ, Burm AG, Hennis PJ, et al. Influence of age on the pharmacokinetics of alfentanil. Gender dependence. Clin Pharmacokinet. 1990;19:416-422.
29. Transon C, Leemann T, Vogt N, et al. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-) fluvastatin. Clin Pharmacol Ther. 1995;58:412-417.
30. Morin S, Loriot MA, Poirier JM, et al. Is diclofenac a valuable CYP2C9 probe in humans? Eur J Clin Pharmacol. 2001;56:793-797.
31. Yasar U, Eliasson E, Forslund-Bergengren C, et al. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol. 2001;57:729-735.
32. Kumar S, Samuel K, Subramanian R, et al. Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide. J Pharmacol Exp Ther. 2002;303:969-978.
33. Lee CR, Pieper JA, Frye RF, et al. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol. 2003;43:84-91.
34. Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial. Thromb Haemost. 2002;87:1075-1076.
35. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet. 2001;40:587-603.
36. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in depression. J Pharmacol Exp Ther. 2000;294:88-95.
37. Mai I, Kruger H, Budde K, et al. Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther. 2000;38:500-502.
38. Nebel A, Schneider B, Baker R, et al. Potential metabolic interaction between St. John's wort and theophylline. Ann Pharmacother. 1999;33:502.
39. Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John's wort. Lancet. 2000;355:548-549.
40. Durr D, Stieger B, Kullak-Ublick GA, et al. St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther. 2000;68:598-604.